GENE ONLINE|News &
Opinion
Blog

2020-03-19| Asia-PacificCOVID-19

Weekly Cover : Fosun and BioNTech Invest USD 135m for Covid-19 Vaccine

by GeneOnline
Share To

0309-0315

By Ching-Hsu Yang, Ph.D. Candidate

1. Fosun and BioNTech Invest USD 135m for Covid-19 Vaccine

According to the press, as well as Fosun and BioNTech, the two firms have stepped into an alliance in China to promote coronavirus vaccines in the global battle against the pandemic. BioNTech said it was in advanced discussions with its existing partner Pfizer over the development of the vaccine outside China.

BioNTech said that it was engaging in early negotiations with its current collaborator, Pfizer, on vaccine production outside of China. Earlier this month, the U.S. drug company listed BioNTech as a strategic business partner.

About BioNTech

BioNTech Biopharmaceutical New Technologies (BioNTech) is a next-generation immunotherapy firm that is developing new cancer and other severe diseases. The Company uses a large variety of analytical research and clinical product tools for the accelerated production of innovative biopharmaceuticals.

2.U.S.-Taiwan Joint Statement

On 18 March 2020, U.S. American Institute in Taiwan (AIT) Director Brent Christensen and Taiwan’s Ministry of Foreign Affairs (MOFA) Foreign Minister Joseph Wu jointly declared the U.S .- Taiwan Joint Statement to further deepen U.S .- Taiwan collaboration and cooperation on the combat against the COVID-19 virus.

According to the statement, both sides would strive to exchange best practices and to collaborate on a variety of activities.

Under the collaboration, the following, inclusive of Research and Development of Rapid Tests; Research and Production of Vaccines Research and Production of Medicines Contact Tracing Techniques and Technology Joint conferences with Scientists and Experts, and Cooperation and Exchanges of Medical Supplies and Equipment and et cetera are areas of concern.

3. AI drug development platform raises $10 million in Series A by Chris Udemans Mar 16, 2020

The Covid-19 pandemic has emphasized the importance of AI in the prevention and detection of pathogens and the ability to rapidly develop innovative therapies for emerging infections.

China-based Stonewise, a project that uses artificial intelligence (AI) to develop drugs, raised nearly $10 million in Series A funding, the firm announced Monday.

About COVID-19

Covid-19, a SARS-like virus first identified in Wuhan, China, last December, has penetrated the world, infecting over 170,000 people. SARS-CoV-2, previously known by 2019 novel coronavirus (2019-nCoV), is a positive-sense single-stranded RNA virus responsible for the pandemic.

See More Information on Coronavirus (COVID-19) | Johns Hopkins Medicine

4. Yale-based Research Lead to First FDA-Approved Traditional Chinese Medication for Liver Cancer

Yale Pharmacology Professor Yung-Chi Cheng, a pioneer in the design of medicines for hepatitis B, AIDS, and HIV, has been exploring a revolutionary theory of exploiting the medicinal ability of conventional Chinese medicine for over two decades.

The Yale-based research team is launching the first international clinical trial for a botanical drug known as YIV-906. The novel botanical medication is expected to allow conventional cancer therapy work better. Professor Cheng has set up a biotech called Yiviva, which has raised $5 million in 2018. This sets a milestone that may change the drug development industry.

About The Drug

YIV-906, having been transferred from Yiviva, a biotech company, originated from a blend of Chinese and Spanish culture, meaning “long live medicine.” The underlying Chinese treatment is a 1,800-year-old recipe for gastrointestinal problems to better treat cancer.

5. Eli Lilly, AbCellera Biologics to Co-develop Covid-19 therapies

Eli Lilly will collaborate with AbCellera to co-develop the most effective of more than 500 anti-SARS-CoV-2 antibodies found via AbCellera’s rapid pandemic response program.

The aim of the companies is to test potential new COVID-19 therapies in patients within the next four months.

Eli Lilly will work with AbCellera to co-develop the most effective of over 500 anti-SARS-CoV-2 antibodies found via AbCellera’s rapid pandemic response program. The goal of the firms is to study potentially new COVID-19 therapies in patients within the next four months.

About Eli Lilly

Eli Lilly and Company develops, produces, manufactures and markets prescription drugs for both humans and livestock. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.

About AbCellera

AbCellera is a biotechnological corporation located in Vancouver that researches and produces human antibodies to counter pandemics and emerging diseases. The organization is well recognized for its leadership role in the Pandemic Prevention Program, a collaboration of the DARPA Biotechnology Office.

 

6. Thermo Fisher’s Coronavirus Detection Kit Gets FDA Emergency Authorization

As Thermo Fisher Scientific confirmed its decision to buy Qiagen earlier this month, experts speculated that Thermo plans to extend its molecular diagnostic arsenal with Qiagen’s diagnostic test QIAstat-Dx for SARS-CoV-2 identification.

While the uncertainty of the situation in China could have played a part in securing the pact, the acquisition program had begun long before the outbreak in Wuhan. Interestingly, the CEO of Thermo Fisher, Marc N. Casper, said that the coronavirus sector was not a significant concern.

This news follows Roche’s announcement of emergency authorization approval for cobas SARS-CoV-2 kit to detect coronavirus in patient samples.

Full Article: https://www.geneonline.com/2020/03/14/thermo-fishers-coronavirus-detection-kit-gets-fda-emergency-authorization/

Related Article: New Study Suggests How Children Might be Persistently Spreading Coronavirus

References
  1. https://www.ait.org.tw/u-s-taiwan-joint-statement/
  2. https://www.reuters.com/article/us-biontech-fosunpharma-vaccine-collabor/biontech-in-china-alliance-with-fosun-over-potential-coronavirus-vaccine-idUSKBN2130O5
  3. https://www.reuters.com/article/us-biontech-fosunpharma-vaccine-collabor/biontech-in-china-alliance-with-fosun-over-potential-coronavirus-vaccine-idUSKBN2130O5
  4. https://technode.com/2020/03/16/ai-drug-development-platform-raises-10-million-in-series-a/?fbclid=IwAR2EjGxHFzrqse11PGbXxfch5TXfQDxFFOyDEF2ey7rFeHNNpGOkxrTanzI
  5. https://www.trialsitenews.com/yale-based-research-in-landmark-study-that-may-lead-to-first-fda-approved-traditional-chinese-medication-for-liver-cancer/?fbclid=IwAR3pIqqmscR-U8V_qZOO9zxpkMDGkJlt4dZCgFJPUdIH9lkR6Z6s3YygaaQ
  6. https://www.reuters.com/article/us-health-coronavirus-lilly/eli-lilly-abcellera-biologics-to-co-develop-coronavirus-therapies-idUSKBN20Z3QC
  7. https://investor.lilly.com/news-releases/news-release-details/abcellera-and-lilly-co-develop-antibody-therapies-treatment

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
Micronbrane Medical Aspires to Further Clinical Collaboration Following the Successful Series A Funding
2022-12-01
LATEST
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
Novartis’ Pluvicto Continues Winning Streak In Prostate Cancer Indication
2022-12-07
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
European Commission Continues Fight with Illumina and Orders Grail Acquisition Divestment
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!